Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China  by Su, ShengFa et al.
International Journal of
Radiation Oncology
biology physics
www.redjournal.orgClinical InvestigationThree-Dimensional Radiation Therapy to the
Primary Tumor With Concurrent Chemotherapy in
Patients With Stage IV Non-Small Cell Lung
Cancer: Results of a Multicenter Phase 2 Study
From PPRA-RTOG, China
ShengFa Su, MD,*,y Tao Li, MD,z Bing Lu, MD,*,y
XiaoHu Wang, MD,x JianCheng Li, MD,k Ming Chen, MD,{
You Lu, MD,# YuJu Bai, MD,** YinXiang Hu, MD,*,y
WeiWei Ouyang, MD,*,y Zhu Ma, MD,*,y
QingSong Li, MD,*,y HuiQin Li, MD,*,y and Yu Wang, MD*,y
*Department of Thoracic Oncology, Affiliated Hospital of Guizhou Medical University, and Guizhou
Cancer Hospital, Guiyang, PR China; yTeaching and Research Section of Oncology, Guizhou Medical
University, Guiyang, PR China; zDepartment of Radiation Oncology, Sichuan Cancer Hospital,
Chengdu, PR China; xDepartment of Radiation Oncology, Gansu Cancer Hospital, Lanzhou, PR China;
kDepartment of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, PR China;
{Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, PR China; #Department of
Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital,
Sichuan University, Chengdu, PR China; and **Department of Oncology, Affiliated Hospital of Zunyi
Medical College, Zunyi, PR ChinaReceived Mar 9, 2015, and in revised form Jul 8, 2015. Accepted for publication Aug 4, 2015.Summary
Primary tumor irradiation
plus concurrent chemo-
therapy for patients with
stage IV non-small cell lungReprint requests to: Bing Lu, MD, Departm
Guizhou Provincial Cancer Hospital, 1 Beijing
Guizhou, PR China. Tel: 86-851-6513076; E-m
or XiaoHu Wang, MD, Department of Rad
Provincial Cancer Hospital, Lanzhou 730050
2302995; E-mail: xhwanggansu@163.com
This work was supported by Science an
Guizhou Province, China, grants SY2010-3078
Int J Radiation Oncol Biol Phys, Vol. 93, No. 4
0360-3016/ 2015 The Authors. Published by
licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.ijrobp.2015.08.012Purpose: The aim of this prospective multi-institutional phase 2 study was to investi-
gate disease control, survival outcomes, and toxicity after thoracic three-dimensional
radiation therapy (3D-RT) with concurrent chemotherapy for newly diagnosed stage
IV non-small cell lung cancer (NSCLC).
Methods and Materials: Eligible patients were 18 to 80 years of age, had a Karnofsky
performance status (KPS) score 70%, and newly diagnosed stage IV NSCLC withent of Thoracic Oncology,
Rd W, Guiyang 550004,
ail: lbgymaaaa@163.com
iation Oncology, Gansu
, PR China. Tel: 86-931-
d Technology Office of
and SY2012-3097.
S. Su and T. Li contributed equally to this work.
Conflict of interest: none.
Supplementary material for this article can be found at
www.redjournal.org.
AcknowledgmentsdThe authors thank Christine F. Wogan for exper-
tise and contributions in language, format, and scientific editing of the
manuscript.
, pp. 769e777, 2015
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Su et al. International Journal of Radiation Oncology  Biology  Physics770cancer produced median
overall and progression-free
survival times of
13.0 months (95% confi-
dence interval [CI]: 11.7-
14.3 months) and 9.0 months
(95% CI: 7.7-10.3) with
acceptable hematologic
toxicity and acute grade 3
rates of radiation pneumo-
nitis of 2.5% and esophagitis
of 6.6%; no patients experi-
enced grade 4 or 5 radiation
toxicity. This treatment
yielded satisfactory survival
outcomes with acceptable
toxicity.limited metastatic disease (defined as involving 3 organs). Patients received
platinum-doublet chemotherapy with concurrent irradiation to the primary tumor. Pri-
mary endpoints were overall survival (OS) and acute toxicity.
Results: From May 2008 to May 2012, 198 eligible patients were enrolled from 7 can-
cer centers. Most patients died with distant metastasis; only 10% died with isolated
primary recurrence. Median OS time was 13.0 months (95% confidence interval
[CI]: 11.7-14.3); OS rates were 53.5% at 1 year, 15.8% at 2 years, and 9.2% at 3 years.
Median progression-free survival (PFS) time was 9.0 months (95% CI: 7.7-10.3); cor-
responding PFS rates were 30.8%, 8.2%, and 6.1%. The 1-year, 2-year, and 3-year
local (primary tumor) control rates were 78.8%, 57.7%, and 55.4%. Multivariate anal-
ysis showed that delivery of 63 Gy to the primary tumor (PZ.014), having a primary
tumor volume <134 cm3 (PZ.008), and having a stable or higher KPS score after
treatment (PZ.01) were independent predictors of better OS. The most common
severe (grades 3-4) acute toxicities were hematologic: leukopenia (37.9%), thrombo-
cytopenia (10.1%), and anemia (6.9%). No patients experienced grade 4 or 5 radiation-
related toxicity; 2.5% had acute grade 3 pneumonitis, and 6.6% had acute grade 3
radiation esophagitis.
Conclusions: Thoracic 3D-RT to the primary tumor with concurrent chemotherapy led
to satisfactory survival outcomes with acceptable toxicity. Radiation dose, primary tu-
mor volume, and PFS after treatment all predicted survival in these patients with
limited-metastasis NSCLC.  2015 The Authors. Published by Elsevier Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
Treatment for patients with stage IV non-small cell lung
cancer (NSCLC) has focused largely on pharmacotherapy.
Platinum-based chemotherapy typically produces response
rates of approximately 30% andmedian survival times of 8 to
10 months, and different chemotherapy regimens have had
similar efficacy (1, 2). The approximately 30% of patients
with epidermal growth factor receptor (EGFR)-sensitive
mutations or anaplastic lymphoma kinase (ALK)-positive
tumors may also receive molecular targeted therapy (3, 4).
Over the past 10 to 15 years, the efficacy of chemotherapy in
NSCLC might have reached a plateau (5, 6), and thus, new
strategies involving combinations of chemotherapy with
other treatment modalities are being explored.
One such strategy, controlling the primary tumor, may
be important in prolonging survival among patients with
advanced NSCLC. Local control of the primary tumor has
been shown to reduce pulmonary symptoms, intrathoracic
disease burden, and bronchial/vascular compression, all of
which are associated with better overall survival (OS) (7-9).
In the era of two-dimensional radiation therapy (2D-RT),
thoracic radiation therapy has been typically used for
palliation of advanced NSCLC (10-12). Retrospective evi-
dence suggests that some patients with stage IV disease
could benefit from aggressive thoracic radiation therapy
beyond palliative irradiation (13-15). However, most such
studies included only small numbers of patients, usually
treated with 2D-RT. Moreover, the role of concurrent
chemotherapy with thoracic radiation therapy for advanced
NSCLC is not well defined (12, 15).Three-dimensional RT (3D-RT) to the primary tumor
given concurrently with chemotherapy for patients with
stage IV NSCLC has produced favorable survival outcomes
in our single-institution prospective study and in other
retrospective studies (15-18); however, these findings still
need to be validated in a multiinstitutional setting. There-
fore, the Pan-Pearl River Area Radiation Therapy Oncology
Group, China (PPRA-RTOG) conducted this multicenter
phase 2 trial to test disease control, survival outcomes, and
toxicity of thoracic 3D-RT with concurrent chemotherapy
for stage IV NSCLC (Chinese Clinical Trial Registry
ChiCTR-TNC-10001026).Methods and Materials
Patient selection
Patients who fulfilled the following criteria were treated
prospectively by a multi-institutional protocol at 1 of 7
cancer centers. Inclusion criteria were as follows: (1) his-
tologically or cytologically confirmed NSCLC; (2) newly
diagnosed stage IV disease (staged according to the 2002
system of the American Joint Committee on Cancer); (3) no
previous anticancer treatment; (4) 18 to 80 years of age; (5)
a Karnofsky performance status (KPS) score 70%; (6) no
contraindications to radiation therapy or chemotherapy; (7)
metastatic disease limited to 3 organs; and (8) presumed
ability to tolerate thoracic radiation therapy to a dose of
36 Gy in 20 fractions. Exclusion criteria were (1) a his-
tory of thoracic surgery, radiation therapy, or
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enrollment; (3) having 2 or more liver metastases; and (4)
previous malignancy or other concomitant malignant
disease. This prospective study was approved by the
participating centers’ institutional review boards, and
informed consent was obtained from all patients.Pretreatment evaluations
All patients underwent fiberoptic bronchoscopy and
contrast-enhanced computed tomography (CT) of the
chest to evaluate the extent of the primary tumor and
regional lymph node status. All patients also underwent
bone scintigraphy, contrast-enhanced CT of the abdom-
inal region, and magnetic resonance imaging (MRI) of
the head to detect distant metastases. Positive findings on
positron emission tomography (PET)/CT or bone scin-
tigraphy required other additional radiologic confirma-
tion (eg, MRI or CT of bone). Pretreatment evaluations
were to be completed within 2 weeks before treatment
was begun.Thoracic radiation therapy protocol
Treatment plans for 3D-CRT or intensity modulated radi-
ation therapy (IMRT) were created using the Pinnacle
(ADAC Laboratories, Milpitas, CA) treatment planning
system (version 7.4f). The gross tumor volume (GTV)
included the thoracic primary tumor plus any enlarged
(>1 cm on short axis) mediastinal lymph nodes and was
outlined on the treatment planning CT scan. The clinical
target volume (CTV) was defined as the GTV plus a 0.6-cm
margin; the planning target volume (PTV) was defined as
the CTV plus another margin of 0.5 to 1.0 cm. The per-
centage of total lung volume receiving 20 Gy (V20) was
to be kept at 32%, the maximum point dose for the spinal
cord to 50 Gy, and the mean esophageal dose to 35 Gy
for all individual treatment plans.
Patients received late-course accelerated hyper-
fractionated radiation therapy (LCAHRT) to the primary
tumor as follows. The first course of radiation therapy was
given in 1.8-Gy fractions, 5 days per week, to a total dose
of 36 Gy; LCAHRT was then delivered in twice-daily
fractions of 1.35 Gy each, separated by 6 to 8 hours per day.
The prescribed dose to the PTV was to be 63 Gy; all pa-
tients were to receive at least 36 Gy. If the above-normal
tissue tolerances could be met, the dose to any residual
primary tumor could be boosted to 72 Gy. Thoracic radi-
ation was given concurrently with the chemotherapy,
beginning within 1 week after beginning the first course of
chemotherapy. No induction chemotherapy was given prior
to radiation.Chemotherapy protocol
Platinum-based doublet chemotherapy (cisplatin in com-
bination with docetaxel, paclitaxel, pemetrexed, or vinor-
elbine) given every 21 to 28 days concurrently with
thoracic radiation, was the first-line therapy for all patients;
gemcitabine was not given because of the risk of its
increasing radiation-related toxicity. After thoracic radia-
tion therapy was completed, patients demonstrating
response or stable disease continued chemotherapy for a
total of 4 to 6 cycles. No maintenance therapy was given.
Patients who received at least 2 cycles of chemotherapy and
thoracic radiation doses of 36 Gy were considered to have
completed treatment according to the protocol.
Evaluation of treatment-related toxicity and
response
Treatment-related acute toxicity was scored with National
Cancer Institute’s Common Terminology Criteria for
Adverse Events version 3.0. During the course of treatment,
routine blood tests were performed at least once per week,
and routine test results of blood, liver, and renal function
and electrocardiography were evaluated before chemo-
therapy. Symptoms suggestive of pneumonitis or esopha-
gitis were evaluated with chest radiography or CT
examination and barium meal radiography. Treatment
response was scored using the Response Evaluation Criteria
in Solid Tumors (RECIST) system (19).
Follow-up evaluations
At 1 month after completion of treatment, patients under-
went CT scanning of the chest and abdominal region and
MRI of the head to assess tumor response. These tests were
then repeated every 3 months for 2 years and every
6 months thereafter. Bone scintigraphy was done every
6 months for 2 years and every 12 months thereafter.
Statistical analyses
The primary objective of this study was to determine OS
and acute toxicity. Secondary objectives were to evaluate
local control and progression-free survival (PFS). All
events were measured from the date treatment was begun,
and statistical tests were done with SPSS version 13.0
software (Chicago, IL). Time to the first defining event
was assessed as follows: OS (death from any cause), local
control (freedom from progression of the primary tumor),
and PFS (alive without progression of disease). Because
of the exploratory nature of the study, no formal sample
size estimation was performed; rather, the sample size was
fixed at 200 patients without a formal sample size
calculation. The Kaplan-Meier method was used to
calculate the OS, local control, and PFS rates over time,
and the curves were compared with log-rank test results.
Table 1 Patient characteristics
Characteristic
Value or no. of patients
Intention-to-treat Per protocol
Group (nZ198) Group (nZ178)
Sex
Male 135 124
Female 63 54
Age (y)
Median (range) 57 (22-80) 57 (22-80)
<60 (y) 115 105
60 (y) 83 73
Tumor histology
Squamous carcinoma 55 51
Adenocarcinoma 124 110
Other 19 17
T status
T1-2 79 69
T3-4 119 109
N status
N0-1 29 27
N2-3 169 151
Prescribed radiation dose (Gy)
Median (range) 58 (2-72) 60 (36-72)
<36 Gy 19 0
36-62 Gy 101 100
63 Gy 78 78
Total no. of chemotherapy cycles
Median (range) 4 (2-6) 4 (2-6)
1 7 0
2 44 34
3 35 34
4 108 106
5 3 3
6 1 1
Metastatic disease status
Single organ 111 102
Bone 41 36
Brain 36 33
Lung 22 22
Other 12 11
Two or three organs 87 76
Bone 58 49
Brain 43 38
Lung 32 29
Liver 9 9
Adrenal 18 16
Distant lymph nodes 7 7
Subcutaneous nodules 6 4
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potential predictors of OS, local control, and PFS.
Because the median survival time for patients with met-
astatic NSCLC who receive chemotherapy is approxi-
mately 8 months (1), we chose 8 months from the start of
treatment as the time point for landmark analyses. All
statistical tests were 2-sided, and P values <.05 were
considered statistically significance.
Results
Patient characteristics
From May 2008 through May 2012, 203 patients were
enrolled in the study. Five patients were considered
ineligible after review (1 for having had thoracic surgery
and 4 with insufficient information [lost case report
forms]). Therefore, 198 patients were included in the
analysis based on the intention-to-treat principle. The type
of chemotherapy received was as follows: 160 patients
(81%) received cisplatin with a taxane (docetaxel or
paclitaxel); 24 patients (12%) received cisplatin and
vinorelbine; and 14 patients (7%) received cisplatin and
pemetrexed. Of the 198 patients, 178 (90%) completed
treatment in accordance with the protocol (ie, received at
least 2 chemotherapy cycles and a thoracic radiation dose
of at least 36 Gy). Of the 20 patients who did not com-
plete treatment, 15 refused (10 for personal reasons [none
of whom had grade 3 or worse toxicity or new metasta-
ses], 2 for grade 4 hematologic toxicity, and 3 for new
metastases), and 5 patients died during treatment (3 of
hematologic toxicity and 2 patients of a concomitant
medical disease). Thus the per-protocol analysis included
only those 178 patients. Clinical characteristics of both
sets of patients are listed in Table 1.
Treatment outcomes
The last follow-up was in April 2014. The follow-up period
ranged from 2.0 to 64.0 months; at the time of last follow-
up, 13 patients were still alive, and the median survival
time for those patients was 37.0 months (range, 12.0-
59.0 months). Most patients died with distant metastasis;
only 10.1% of patients died with primary recurrence alone
(Table 2). The median OS time for all patients was
13.0 months (95% confidence interval [CI]: 11.7-14.3), and
the OS rates at 1, 2, and 3 years were 53.5%, 15.8%, and
9.2%, respectively. Corresponding local control rates were
78.8%, 57.7%, and 55.4%, respectively. The median PFS
time was 9.0 months (95% CI: 7.7-10.3), and the 1-, 2-, and
3-year PFS rates were 30.8%, 8.2%, and 6.1%, respectively
(Fig. 1). Only 8 patients were treated with epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI); the median OS time for those patients was
17.0 months (95% CI: 12.6-25.4). No survival differences
were noted between patients treated with and those nottreated with EGFR-TKI (c2 Z 2.769, PZ.060). At
1 month after completion of treatment, 178 patients were
evaluable for tumor response: 2 (1%) had a complete
response, 120 (67%) had a partial response, 38 (21%) had
stable disease, and 18 (10%) had progressive disease.
For the 178 patients in the per-protocol analysis, the
median OS time was 14.0 months (95% CI: 12.6-15.4), and
the OS rates were 56.7% at 1 year, 17.0% at 2 years, and
9.6% at 3 years. Corresponding local control rates were
Table 2 Vital status of patients at the time of analysis
Vital status
No. of patients (%)
Intention-to-treat
group (nZ198)
Per protocol
group (nZ178)
Died with distant
metastasis
116 (58.6) 108 (60.6)
Died with distant
metastasis and primary
recurrence
35 (17.7) 31 (17.4)
Died with primary
recurrence
20 (10.1) 17 (9.6)
Died of treatment toxicity 3 (1.5) 0 (0)
Died of other medical
disease/condition
4 (2.0) 2 (1.1)
Died of unknown causes 7 (4.0) 7 (3.9)
Alive 13 (6.6) 13 (7.3)
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time was 10.0 months (95% CI: 8.5-11.5), and the 1-, 2-,
and 3-year PFS rates were 32.6%, 8.6%, and 6.2%,
respectively. These values did not differ from those for the
198 patients in the intent-to-treat group.
Factors associated with outcomes
Univariate analysis showed that GTV, post-treatment KPS
score, and radiation dose to the primary tumor were
significantly associated with OS and local control (Table 3).
Receipt of radiation therapy to metastatic disease sites was
associated with PFS and was marginally associated with
OS. Tumor histology, number of chemotherapy cycles
received, and primary tumor location (central vs peripheral)
were all associated with local control. GTV, post-treatment
KPS score, and radiation therapy to metastatic sites were
associated with PFS (Table 3).
In the landmark analysis using 8 months from treatment
start as the landmark time point, OS differed for patients100
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Fig. 1. Proportions of local control (LC), overall survival
(OS), and progression-free survival (PFS) for all patients
over time.who had received a thoracic dose of 63 Gy: the 1-, 2-, and
3-year OS rates were 72.6%, 32.3%, and 21.6%, respec-
tively, for those patients versus 72.6%, 13.3%, and 5.6%,
respectively, for patients who received <63 Gy
(c2 Z 5.587, PZ.018) (Fig. 2); patient and tumor char-
acteristics were well balanced across these 2 groups
(Supplementary Table; available online at www.redjournal
.org). OS rates at 8 months were no different for patients
who had received >2 cycles of chemotherapy compared to
those who had received 2 cycles (c2 Z 1.246, PZ.264).
Radiation dose also interacted with GTV and primary
tumor location (central vs peripheral) in terms of influ-
encing OS. Patients who received the higher dose for
smaller disease (63 Gy for <134 cm3 tumors) had OS
rates of 68.4% at 1 year, 28.9% at 2 years, and 23.7% at
3 years; corresponding rates for patients receiving <63 Gy
were 60.8%, 16.2%, and 8.1% (c2Z 4.184, PZ.041). The
higher dose also remained beneficial for OS among patients
with larger tumors (134 cm3; c2 Z 7.078, PZ.008). In
terms of tumor location, the patients with central tumors
who got the higher radiation dose had better OS
(c2 Z 10.175, PZ.001), but radiation dose did not affect
OS in patients with peripheral tumors (c2 Z 0.307,
PZ.579).
Multivariate analysis showed that receiving 63 Gy to
the primary tumor, having a GTV <134 cm3, and having
stable or increased (better) KPS score after treatment
independently predicted better OS (PZ.014, PZ.008, and
PZ.010). Primary-tumor location, having a GTV
<134 cm3, and receiving 63 Gy to the primary tumor
independently predicted improved local control (PZ.004,
PZ.035, and PZ.001). Having a GTV <134 cm3 and
stable or increased KPS score after treatment also inde-
pendently predicted PFS (PZ.048 and PZ.001). Receipt
of radiation therapy to metastatic sites did not affect OS
(PZ.400), PFS (PZ.465), or local control (PZ.117) in
multivariate analysis.
Treatment complications
Hematologic toxicity was the most common and severe
complication. The incidence of acute grade 3 or 4 leuko-
penia was 37.9%, and 2 patients with grade 4 leukopenia
died from severe pulmonary infection. Twenty patients
(10.1%) had grade 3 or 4 thrombocytopenia, and 1 patient
with brain metastasis died of grade 3 thrombocytopenia
with vasogenic brain edema. The incidence of grade 3 or 4
anemia was 6.9%. Rates of severe (grade 3) acute radi-
ation pneumonitis and esophagitis, evaluable in 193 pa-
tients, were 2.5% and 6.6%, respectively, (Table 4).
Discussion
In the current study, we evaluated toxicity, disease control,
and survival outcomes after 3D-RT to the primary tumor
with concurrent chemotherapy for patients with stage IV
Table 3 Univariate analysis of factors potentially associated with survival outcomes
Variable No
Local control rate (%) Progression-free survival rate (%) Overall survival rate (%)
1 y 2 y 3 y Statistic 1 y 2 y 3 y Statistic 1 y 2 y 3 y Statistic
Sex
Male 135 81.1 56.1 56.1 c2Z0.366 36.3 7.4 5.0 c2Z0.244 49.6 14.1 6.8 c2Z3.306
Female 63 73.1 59.1 52.6 PZ.545 41.3 9.9 6.6 PZ.621 61.9 19.5 14.3 PZ.069
Age (y)
<60 115 79.2 54.1 49.2 c2Z0.218 35.7 6.1 3.0 c2Z0.478 53.9 13.9 6.7 c2Z0.223
60 83 77.4 62.2 49.8 PZ.641 41.0 11.2 8.7 PZ.489 53.0 18.5 12.3 PZ.637
Tumor histology
Non-squamous 124 82.2 66.1 62.7 c2Z10.863 41.1 9.0 4.5 c2Z2.172 55.9 17.7 7.7 c2Z1.165
Squamous 74 69.4 35.7 35.7 PZ.001 32.4 6.8 6.8 PZ.141 47.3 10.9 10.9 PZ.280
Location of primary tumor
Central 98 68.4 53.9 52.1 c2Z4.413 34.0 7.4 6.4 c2Z1.225 46.9 14.3 8.6 c2Z0.808
Peripheral 100 87.5 60.9 60.9 PZ.036 41.4 9.3 4.7 PZ.268 60.0 17.3 8.1 PZ.369
T status
T1-2 79 78.3 54.7 47.8 c2Z0.188 38.0 6.5 2.6 c2Z0.217 59.5 11.6 3.9 c2Z0.699
T3-4 119 78.3 58.5 58.5 PZ.665 37.8 9.2 7.4 PZ.641 49.6 18.5 13.0 PZ.403
N status
N0-1 29 81.6 66.9 53.5 c2Z0.023 44.8 18.7 11.2 c2Z3.104 65.5 25.5 12.7 c2Z2.817
N2-3 169 77.7 55.6 55.6 PZ.878 36.7 6.5 4.6 PZ.078 51.5 14.2 8.6 PZ.093
Gross tumor volume (cm3)
<134 96 84.9 65.2 61.7 c2Z5.286 40.4 10.4 8.1 c2Z7.315 65.6 22.2 13.8 c2Z11.782
134 102 71.9 48.8 48.8 PZ.021 33.0 5.5 2.7 PZ.007 42.2 9.8 5.0 PZ.001
Pretreatment KPS
80 141 78.1 56.6 53.2 c2Z0.132 39.0 5.1 2.9 c2Z1.402 53.9 15.1 8.2 c2Z1.262
>80 57 79.3 59.5 59.5 PZ.716 35.1 15.8 11.8 PZ.236 52.6 17.5 11.7 PZ.261
Post-treatment KPS
Increased or stable 148 82.0 64.2 61.2 c2Z10.440 42.6 10.3 6.4 c2Z14.545 60.5 24.8 10.9 c2Z11.787
Decreased 50 66.0 31.7 31.7 PZ.001 24.0 2.0 2.0 PZ.000 33.3 11.8 5.9 PZ.001
No. of metastatic organs
1 111 80.2 63.0 59.3 c2Z0.500 41.4 9.9 8.9 c2Z1.878 55.0 18.9 12.1 c2Z2.834
>1 87 76.0 48.4 48.4 PZ.480 33.3 6.0 1.2 PZ.171 51.7 11.8 5.2 PZ.092
Prescribed radiation dose
<63 Gy 120 71.5 41.7 37.5 c2Z16.489 38.3 6.2 3.3 c2Z0.569 50.8 9.3 4.0 c2Z8.115
63 Gy 78 88.8 80.1 80.1 PZ.000 37.2 11.5 8.7 PZ.451 57.7 25.6 17.2 PZ.004
No. of chemotherapy cycles
<4 86 70.2 46.8 41.6 c2Z6.068 29.4 5.1 3.8 c2Z1.678 47.7 11.9 6.0 c2Z2.764
4 112 85.2 66.7 66.0 PZ.014 36.2 13.0 10.6 PZ.195 58.0 18.8 11.7 PZ.096
Radiation to all metastases
Yes 82 77.0 57.3 52.9 c2Z0.418 48.8 11.0 9.8 c2Z4.461 63.4 17.1 13.3 c2Z3.581
No 116 79.3 57.1 57.1 PZ.518 30.2 6.2 1.6 PZ.035 46.6 14.9 5.8 PZ.058
Abbreviation: KPS, Karnofsky performance status.
Su et al. International Journal of Radiation Oncology  Biology  Physics774NSCLC with metastases in up to 3 organs. Our median OS
time, 13.0 months, and our finding that primary tumor
volume and radiation dose to the primary tumor inde-
pendently predicted OS are similar to results from
previous prospective single-center studies and other
retrospective studies (15-18). Because only 8 patients in
the current study received EGFR-TKI treatment and no
differences in OS were observed between patients given
EGFR-TKI and those not given EGFR-TKI, we cannot
comment on whether EGFR-TKI would affect survival.
The response rate and median survival times in this study
were better than those in a randomized trial conducted by
the Italian Lung Cancer Project (ILCP) that compared
outcomes after three types of platinum-based doubletchemotherapy (gemcitabine/cisplatin, paclitaxel/carbo-
platin, vinorelbine/cisplatin) for patients with advanced
NSCLC (5). Corresponding median survival times in that
study were 9.8, 10.0, and 9.5 months, respectively.
Our results may reflect our use of thoracic radiation, or
they could reflect differences between the patient pop-
ulations in the 2 trials, as approximately 20% of the pa-
tients in the Italian trial had stage IIIB NSCLC and 70%
of those with metastatic disease had metastatic lesions at a
single site (5).
For patients with metastatic disease, clinicians tend to
attach more importance to systemic therapy to control the
metastatic lesions than to local treatment to control the
primary tumor. However, in our study most failures were
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Fig. 2. Landmark analysis: overall survival in patients
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tumor failure alone, pointing to the need for more effective
treatments for distant metastases in the future.
Should aggressive or palliative radiation doses be
delivered to the primary tumor in patients with stage IV
NSCLC? The answer is not well defined. Consistent with
previous findings (15, 18), we found that aggressive irra-
diation of the primary tumor was associated with better OS
and local control. Another issue is the extent of metastatic
disease, particularly the definition of oligometastatic
NSCLC, which ranges from the presence of a single
metastatic lesion to a single organ in some studies to
multiple lesions in several organs in others (13-16, 18, 20).
Patients in the current study had metastases confined to 3 or
fewer organs (regardless of the number of metastatic le-
sions in each organ). Collectively, these studies suggest that
aggressive thoracic radiation is important in improving OS
for patients with oligometastatic NSCLC (14-16, 18, 20).
Other evidence in support of this idea comes from a sys-
tematic review of 13 randomized controlled trials of palli-
ative thoracic radiation in which Fairchild et al (10) found
that higher-dose radiation improved survival and symptom
palliation compared with lower-dose radiation schedules.
At present, no randomized evidence is available to
recommend aggressive or palliative radiation with systemic
chemotherapy to manage the primary tumor in patients with
limited stage IV NSCLC. We are currently conducting aTable 4 Acute toxicity*
Toxicity Grade 0-1 Grade 2
Gastrointestinal 103 (52.0) 73 (36.9)
Leukopenia 56 (28.3) 65 (32.8)
Thrombocytopenia 160 (80.8) 17 (8.6)
Anemia 143 (72.2) 41 (20.7)
Pneumonitisy 169 (87.6) 19 (9.6)
Esophagitisy 125 (63.6) 55 (27.8)
* Values are number of events (%).
y Evaluable in 193 patients.multicenter phase 3 trial to address this question by testing
the effects of different thoracic doses on survival of patients
with limited metastasis from NSCLC.
From a clinical standpoint, larger primary tumors are
more difficult to control than smaller ones, both locally and
systemically (21, 22). Our study showed that patients with
smaller primary tumors had better survival outcomes, a
finding consistent with those of other studies (15, 17).
When the entire group was divided according to GTV
(<134 cm3 vs 134 cm3), higher radiation doses to the
primary tumor retained significance for predicting
improved survival outcomes. Furthermore, we found that
central tumors but not peripheral tumors can benefit from
aggressive radiation for OS, perhaps because uncontrolled
central disease is more likely to cause deadly bronchial/
vascular compression and hemoptysis than is uncontrolled
peripheral disease. Higginson et al (9) reported that patients
with advanced NSCLC and bulky central disease, bron-
chial/vascular compression, and/or pulmonary symptoms
had worse OS. Our results suggest that aggressive irradia-
tion of the primary tumor improved OS regardless of pri-
mary tumor volume and that the location of the primary
tumor may be useful for selecting which patients should
undergo aggressive radiation therapy in this setting.
Prognosis is well known to be associated with pretreat-
ment performance status (PS) (15, 18); however, the effect
of PS after treatment on survival is seldom reported. Our
finding that KPS scores that remained stable or increased
after treatment independently predicted better survival
suggest that PS after treatment may be helpful as an indi-
cator of overtreatment when multimodality therapy is used
for stage IV NSCLC.
The long-term survival benefit from concurrent chemo-
radiation therapy has been well established for locally
advanced NSCLC (23, 24). However, consensus has yet to
be reached on whether chemotherapy should be given
concurrently with radiation for stage IV NSCLC. In one
phase 3 study, Ball et al (25) found that palliative radiation
with concurrent fluorouracil did not improve OS over ra-
diation alone; however, fluorouracil is rarely used at present
for NSCLC, and the radiation in that study was given as
2D-RT at palliative doses (25). Superior survival in the
current study could be attributable to our use of taxanes
(26); indeed, Lopez et al (15) showed that patients with
metastatic NSCLC who received concurrent platinum-and-Grade 3 Grade 4 Grade 5
21 (10.6) 1 (0.5) -
51 (25.8) 24 (12.1) 2 (1.0)
12 (6.1) 8 (4.0) 1 (0.5)
9 (4.4) 5 (2.5) -
5 (2.5) 0 -
13 (6.6) 0 -
Su et al. International Journal of Radiation Oncology  Biology  Physics776taxaneebased chemotherapy with radiation may have had
better OS than those who did not receive chemoradiation
therapy. We further speculate that use of modern radiation
therapy techniques (IMRT or 3D-CRT) and higher doses of
radiation (median dose, 63 Gy) also contributed to
improved survival through improving the local control of
thoracic tumors.
Another issue with the use of concurrent chemo-
radiation for advanced NSCLC relates to its potential
toxicity. Rates of grade 3 to 4 toxicity in our study were
similar to those in a previous single-center study (16).
Although 3 patients in the current study died with hema-
tologic toxicity (2 neutropenia and 1 thrombocytopenia),
mortality rates from chemotherapy alone for advanced
NSCLC have also ranged from 1.5% to 3.0% (1, 5). Rates
of pneumonitis and esophagitis in our study were not
increased compared with studies of concurrent chemo-
radiation therapy for locally advanced NSCLC (23, 24).
Thus, in general, treatment-related hematologic or non-
hematologic toxicity in the current study can be consid-
ered acceptable.
We acknowledge several limitations to the current study.
Although we found that receipt of 63 Gy was associated
with better OS, the range of doses prescribed to the thoracic
lesions was broad at 36 to 72 Gy, and the choice of dose
depended on factors such as PS and tumor burden, leading
to possible selection bias. We attempted to account for this
bias by choosing 8 months from the start of treatment as the
time point for landmark analyses, and comparing patient
characteristics between the 63 Gy group and <63 Gy
group and found that characteristics were well balanced
across these two groups (Supplementary Table; available
online at www.redjournal.org). Moreover, we found that
radiation dose remained a predictor of improved survival
outcomes even when patient and treatment factors were
considered in multivariate analyses. Finally, we recognize
that our LCAHRT treatment regimen is not commonly used
outside of China. However, it is considered optional for
NSCLC and esophageal carcinoma in China and has shown
tolerable toxicity and similar or better survival than con-
ventional fractionated radiation (27-29). We used this
regimen to shorten overall radiation treatment time.
Conclusions
In summary, chemotherapy given concurrently with 3D-RT
to the primary tumor produced satisfactory outcomes with
acceptable toxicity for selected patients with limited stage
IV NSCLC. Radiation dose to the primary tumor, primary
tumor volume, and PS after treatment were the main con-
tributors to OS. Consistent with conclusions from other
studies (15, 16, 18), we found that aggressive radiation to
the primary tumor improved survival outcomes for a subset
of patients with metastatic NSCLC. Further randomized
trials are warranted to evaluate the optimal thoracic radia-
tion dose (palliative or aggressive) in combination withchemotherapy, and additional trials are necessary to
investigate the value of thoracic radiation in combination
with targeted therapy or immunotherapy for patients with
advanced NSCLC.References
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